Vas Narasimhan, Novartis CEO (Jason Alden/Bloomberg via Getty Images)

No­var­tis pledges $250M in R&D fund­ing for ne­glect­ed trop­i­cal dis­eases, malar­ia

Over the next five years, No­var­tis is pledg­ing to pour $250 mil­lion in­to R&D for new treat­ments of ne­glect­ed trop­i­cal dis­eases and malar­ia — with the ul­ti­mate goal of elim­i­nat­ing these dis­eases.

“Over the past decade, great progress has been made against NTDs, but there is still a lot more work to be done,” CEO Vas Narasimhan said in a state­ment.

About 1.7 bil­lion peo­ple still suf­fer from NTDs around the world, most­ly in im­pov­er­ished ar­eas, and while malar­ia doesn’t fall in the NTD cat­e­go­ry, it still af­fects 241 mil­lion peo­ple and kills hun­dreds of thou­sands of chil­dren every year.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.